Topoisomerase mutations and efflux are associated with fluoroquinolone resistance in Enterococcus faecalis

被引:23
|
作者
Oyamada, Yoshihiro
Ito, Hideaki
Inoue, Matsuhisa
Yamagishi, Jun-ichi
机构
[1] Dainippon Sumitomo Pharma Co Ltd, Pharmacol Res Labs, Osaka 5640053, Japan
[2] Kitasato Univ, Grad Sch Med Sci, Dept Environm Infect Dis, Sagamihara, Kanagawa 2288555, Japan
[3] Dainippon Sumitomo Pharma Co Ltd, Technol Res & Dev Ctr, Fukushima Ku, Osaka 5530001, Japan
关键词
D O I
10.1099/jmm.0.46636-0
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
To understand better the mechanisms of fluoroquinolone resistance in Enterococcus faecalis, fluoroquinolone-resistant mutants isolated from Ent. faecalis ATCC 29212 by stepwise selection with sparfloxacin (SPX) and norfloxacin (NOR) were analysed. The results showed the following. (i) In general, fluoroquinolone-resistance mechanisms in Ent faecalis are similar to those in other Gram-positive bacteria, such as Staphylococcus aureus and Streptococcus pneumoniae, namely, mutants with amino acid changes in both GyrA and ParC exhibited high fluoroquinolone resistance, and single GyrA mutants and a single ParC mutant were more resistant to SPX and NOR, respectively, than the parent strain, indicating that the primary targets of SPX and NOR in Ent. faecalis are DNA gyrase and topoisomerase IV, respectively. (ii) Alterations in GyrB (Delta KGA, residues 395-397) and ParE (Glu-459 to Lys) were associated with fluoroquinolone resistance in some mutants. Moreover, the facts that the NOR MIC, but not the SPX MIC, decreased in the presence of multidrug efflux pump inhibitors, that NOR accumulation decreased in the cells, and that the EmeA mRNA expression level did not change, strongly suggested that a NorA-like efflux pump, rather than EmeA, was involved in resistance to NOR.
引用
收藏
页码:1395 / 1401
页数:7
相关论文
共 50 条
  • [11] Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump
    Oethinger, M
    Kern, WV
    Jellen-Ritter, AS
    McMurry, LM
    Levy, SB
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (01) : 10 - 13
  • [12] Type II topoisomerase mutations in Bacillus anthracis associated with high-level fluoroquinolone resistance
    Bast, DJ
    Athamna, A
    Duncan, CL
    de Azavedo, JCS
    Low, DE
    Rahav, G
    Farrell, D
    Rubinstein, E
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (01) : 90 - 94
  • [13] Mutations in gyrase and topoisomerase genes associated with fluoroquinolone resistance in Salmonella serovars from retail meats
    Yang, Baowei
    Xi, Meili
    Cui, Shenghui
    Zhang, Xiuli
    Shen, Jinling
    Sheng, Min
    Qu, Dong
    Wang, Xin
    Meng, Jianghong
    FOOD RESEARCH INTERNATIONAL, 2012, 45 (02) : 935 - 939
  • [14] Characterization of emeA, a norA homolog and multidrug resistance efflux pump, in Enterococcus faecalis
    Jonas, BM
    Murray, BE
    Weinstock, GM
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (12) : 3574 - 3579
  • [15] Pharmacodynamic characterization of efflux and topoisomerase IV-mediated fluoroquinolone resistance in Streptococcus pneumoniae
    Madaras-Kelly, KJ
    Daniels, C
    Hegbloom, M
    Thompson, M
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (02) : 211 - 218
  • [16] Fluoroquinolone resistance associated with target mutations and active efflux in orophalyngeal colonizing isolates of viridans group streptococci
    Guerin, F
    Varon, E
    Hoï, AB
    Gutmann, L
    Podglajen, I
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) : 2197 - 2200
  • [17] Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis
    Kanematsu, E
    Deguchi, T
    Yasuda, M
    Kawamura, T
    Nishino, Y
    Kawada, Y
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (02) : 433 - 435
  • [18] Alterations in GyrA and ParC associated with fluoroquinolone resistance in Enterococcus faecium
    El Amin, N
    Jalal, S
    Wretlind, B
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (04) : 947 - 949
  • [19] Role of topoisomerase mutations, plasmid mediated resistance (qnr) and acrAB efflux pump in fluoroquinolone resistant clinical isolates of avian Escherichia coli
    Yaqoob, M.
    Wang, L. P.
    Memon, J.
    Kashif, J.
    Umar, S.
    Naseer, Z.
    Iqbal, M. F.
    Fiaz, M.
    Lu, C. P.
    MOLECULAR GENETICS MICROBIOLOGY AND VIROLOGY, 2017, 32 (01) : 49 - 54
  • [20] Role of topoisomerase mutations, plasmid mediated resistance (qnr) and acrAB efflux pump in fluoroquinolone resistant clinical isolates of avian Escherichia coli
    M. Yaqoob
    L. P. Wang
    J. Memon
    J. Kashif
    S. Umar
    Z. Naseer
    M. F. Iqbal
    M. Fiaz
    C. P. Lu
    Molecular Genetics, Microbiology and Virology, 2017, 32 : 49 - 54